Navigation Links
Children's National researcher co-authors study on transitioning cystic fibrosis care
Date:10/23/2013

Washington, DC Children's National pediatrician and researcher, Lisa Tuchman, MD, MPH, co-authored a new study on cystic fibrosis (CF) care that found patients had a less rapid decline in pulmonary function and no other significant health-related changes after transitioning from pediatric to adult care. The findings of this study contradict reports of negative health outcomes after transition from pediatric to adult care for other chronic childhood illnesses such as HIV and sickle cell disease. The study was published online in Pediatrics, the official journal of the American Academy of Pediatrics.

In this study, Dr. Tuchman and co-author Michael Schwartz, MD, MSCE, Pediatric Pulmonary Medicine & Cystic Fibrosis Center, Lehigh Valley Health Network, retrospectively examined patients using the Cystic Fibrosis Foundation Patient Registry. They identified patients who transferred from pediatric to adult programs (transfer-positive patients) and matched them based on similar baseline characteristics, such as gender, race, age, and CF genotype, with patients who remained in pediatric programs (transfer-negative patients). The authors measured differences in outcomes such as pulmonary function, nutritional status, care use, and home intravenous antibiotic events per year in both the transfer-positive and transfer-negative patients to determine if transfer from pediatric to adult care made a difference.

One of the barriers in transitioning from pediatric to adult CF care among patients and pediatric providers is concern that the quality of adult care may not be comparable. This study begins to close a critical gap in research on the topic of health outcomes and transitioning care in patients with CF that can help guide providers and their transition-age patients. It is the first study on CF to track patients during the time of expected healthcare transition, and compare outcomes with statistically similar individuals who do not transfer care over the same period.

"Our results show that when you look at individuals with CF who are similar in almost every way, when one transfers to adult care and one stays in pediatric care, there are essentially no differences in short-term health outcomes," said Dr. Tuchman. "With nearly half of all the individuals with cystic fibrosis older than 18, the systematic process of transitioning care utilized by CF programs serves as a model of safe and successful transition. By instituting clear guidelines, resource-sharing and care coordination between pediatric and adult care teams, this model of care can be used to improve transitions for all young adults with special healthcare needs."


'/>"/>

Contact: Emily Hartman
EHartman@ChildrensNational.org
202-476-4500
Children's National Medical Center
Source:Eurekalert

Related medicine news :

1. Sensory Processing Disorder Foundation Celebrates National Sensory Awareness Month
2. HealthPostures and Electronic Office Environments to Attend National Minority Supplier Development Council Conference and Business Opportunity Fair
3. Lawrence Buckfire Asks Parents To Get Behind National Teen Driver Safety Week
4. Narconon International Presents to the 14th Latin American Congress of Clinical Toxicology and Chemical Safety
5. ¡Vive tu vida! Get Up! Get Moving!® 10-City Tour Announced by National Alliance for Hispanic Health
6. Improve Indoor Air Quality with Air Scrubber Plus During National Home Indoor Air Quality and Awareness Month
7. Tummy Calm to Exhibit at 2013 AAP National Conference
8. 4 leading international Wiley journals become open access
9. Enhanced Maternity Benefits for Pacific Prime Clients with Bupa International
10. Fatigue to Fit Centers Houston with the CDC Promotes the Theme "Lead Free Kids for the Healthy Future" from Oct 20-26, 2013 as the National Lead Poisoning Prevention Week
11. Canton, Michigan is About to Get National Exposure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2017)... Tampa, Fla. (PRWEB) , ... June 24, 2017 ... ... Fla., is now offering genetic testing for medications in select Florida and Texas ... of pharmacogenomics. , This new application of genetic testing recognizes the role ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island ... Care Management Alerts and Dashboards, an innovative new service enabling healthcare providers to ... Care Management Alerts and Dashboards provide near real-time data about patients admitted to ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Military Officers Association of America (MOAA) announced ... Veterans Affairs, retired Marine Col. Thomas G. Bowman. , Bowman currently serves as the ... an intimacy with the issues and challenges veterans face with the VA. Following a ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... The Aesthetic ... facelift . Dr. Talei has come up with a proprietary technique that he calls ... lifts tissues that have dropped. For all ages, patients can expect to look refreshed, ...
(Date:6/23/2017)... Santa Monica, CA (PRWEB) , ... June 23, 2017 , ... ... PureLife as the endorsed amalgam separator supplier for CDA members. As part of the ... a reduced price of $99, saving more than $400 off the retail value. This ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... ALTO, Calif. , June 9, 2017 ... device company focused on the design, manufacture, sale and ... the market on the progress of its commercial roll-out ... is now available in more than one hundred (100) ... AeroForm offers a needle-free alternative for ...
(Date:6/7/2017)... , June 7, 2017 Endo International ... June 7, 2017, the Hon. Joseph R. Goodwin ... of West Virginia , entered a ... Inc. Pelvic Repair System Products Liability Litigation (the "MDL") ... MDL cases to provide expert disclosures on specific causation ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
Breaking Medicine Technology: